HRP20030585B1 - Improved mycoplasma hyopneumoniae bacterin vaccine - Google Patents

Improved mycoplasma hyopneumoniae bacterin vaccine

Info

Publication number
HRP20030585B1
HRP20030585B1 HR20030585A HRP20030585A HRP20030585B1 HR P20030585 B1 HRP20030585 B1 HR P20030585B1 HR 20030585 A HR20030585 A HR 20030585A HR P20030585 A HRP20030585 A HR P20030585A HR P20030585 B1 HRP20030585 B1 HR P20030585B1
Authority
HR
Croatia
Prior art keywords
mycoplasma hyopneumoniae
vaccine
hyopneumoniae bacterin
bacterin vaccine
composition
Prior art date
Application number
HR20030585A
Other languages
English (en)
Croatian (hr)
Inventor
Hsien-Jue, (Steve) Chu
Li Wumin
Xu Zhichang
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22972978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20030585(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth filed Critical Wyeth
Publication of HRP20030585A2 publication Critical patent/HRP20030585A2/xx
Publication of HRP20030585B1 publication Critical patent/HRP20030585B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HR20030585A 2000-12-19 2003-07-18 Improved mycoplasma hyopneumoniae bacterin vaccine HRP20030585B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25663700P 2000-12-19 2000-12-19
PCT/US2001/047865 WO2002049666A2 (en) 2000-12-19 2001-12-11 Mycoplasma hyopneumoniae bacterin vaccine

Publications (2)

Publication Number Publication Date
HRP20030585A2 HRP20030585A2 (en) 2005-06-30
HRP20030585B1 true HRP20030585B1 (en) 2008-03-31

Family

ID=22972978

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030585A HRP20030585B1 (en) 2000-12-19 2003-07-18 Improved mycoplasma hyopneumoniae bacterin vaccine

Country Status (28)

Country Link
US (4) US20020131980A1 (me)
EP (1) EP1343525B1 (me)
JP (2) JP5074656B2 (me)
KR (1) KR100874119B1 (me)
CN (1) CN1296095C (me)
AR (1) AR033410A1 (me)
AT (1) ATE359813T1 (me)
AU (2) AU2899302A (me)
BG (1) BG66213B1 (me)
BR (1) BRPI0116249B1 (me)
CY (1) CY1106669T1 (me)
CZ (1) CZ307075B6 (me)
DE (1) DE60127994T2 (me)
DK (1) DK1343525T3 (me)
ES (1) ES2283452T3 (me)
HK (1) HK1056513A1 (me)
HR (1) HRP20030585B1 (me)
HU (1) HU227431B1 (me)
ME (1) ME00570B (me)
MX (1) MXPA03005357A (me)
MY (1) MY129765A (me)
NZ (1) NZ526904A (me)
PL (1) PL211174B1 (me)
PT (1) PT1343525E (me)
RS (1) RS51536B (me)
TW (1) TWI308872B (me)
WO (1) WO2002049666A2 (me)
ZA (1) ZA200305545B (me)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
GB0400264D0 (en) * 2004-01-07 2004-02-11 Polytherics Ltd Complexes
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
KR101436794B1 (ko) 2005-12-29 2014-09-04 베링거잉겔하임베트메디카인코퍼레이티드 다가 ｐｃｖ2 면역원성 조성물 및 이러한 조성물의 제조방법
MX356667B (es) 2005-12-29 2018-06-08 Boehringer Ingelheim Vetmedica Inc Uso de una composicion inmunogenica de pcv2 para reducir los sintomas clinicos en cerdos.
WO2008073464A2 (en) 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
DK2094872T4 (da) 2006-12-15 2020-05-18 Boehringer Ingelheim Animal Health Usa Inc Behandling af anti-PCV2-antistofseropositive svin med PCV2-antigen
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
UA98812C2 (ru) 2007-11-06 2012-06-25 Вайет Ллк Авирулентная активированная живая вакцина mycoplasma hyopneumoniae
WO2009126356A2 (en) 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
CN102119033B (zh) * 2008-06-25 2015-04-08 布拉施生物技术有限责任公司 用于增强促生长素抑制素免疫原性的组合物和方法
ES2579935T3 (es) * 2009-05-19 2016-08-17 Bioproperties Pty Ltd Cepa de vacuna de Mycoplasma Hyopneumoniae sensible a temperatura y uso de la misma
WO2010140377A1 (ja) 2009-06-04 2010-12-09 独立行政法人産業技術総合研究所 マイコプラズマ感染症用ワクチン
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
CN107213461B (zh) * 2009-09-10 2022-03-15 勃林格殷格翰动物保健美国公司 包含含有皂苷的佐剂的新疫苗制剂
SG184804A1 (en) 2010-04-30 2012-11-29 Temasek Life Sciences Lab Ltd Universal vaccine against h5n1 lineages
WO2013149017A1 (en) * 2012-03-28 2013-10-03 Kansas State University Research Foundation Vaccine adjuvant
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
CN103623400B (zh) * 2012-08-24 2016-08-17 普莱柯生物工程股份有限公司 抗猪支原体肺炎、传染性胸膜肺炎疫苗组合物及制备方法
UA121097C2 (uk) 2012-12-28 2020-04-10 Бьорінгер Інгельхайм Ветмедіка Гмбх Імуногенна композиція, що містить антигени мікоплазм
PT2938747T (pt) 2012-12-28 2019-08-01 Boehringer Ingelheim Vetmedica Gmbh Método de preparação de uma vacina de micoplasma
CN104338128B (zh) * 2013-07-31 2017-09-05 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CA2924228C (en) 2013-10-02 2024-01-16 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 protein variant and virus like particles composed thereof
CA3022006A1 (en) * 2016-05-11 2017-11-16 Phibro Animal Health Corporation A composition comprising antigens and a mucosal adjuvant and a method for using
WO2019110486A1 (en) * 2017-12-04 2019-06-13 Intervet International B.V. Canine lyme disease vaccine
CN108324941A (zh) * 2018-04-03 2018-07-27 林淑卿 猪疾病疫苗用佐剂及其制备方法
CN117100851A (zh) * 2023-10-23 2023-11-24 成都依思康生物科技有限公司 一种佐剂、疫苗组合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0315153A2 (en) * 1987-11-03 1989-05-10 Syntex (U.S.A.) Inc. Vaccine adjuvant
WO1995030437A1 (en) * 1994-05-10 1995-11-16 American Home Products Corporation Improved modified live brsv vaccine
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3790665A (en) 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPH0832637B2 (ja) 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
ES2052685T3 (es) 1987-03-17 1994-07-16 Akzo Nv Metodo para producir un adyuvante libre.
US5240706A (en) 1989-04-07 1993-08-31 Ml Technology Ventures, L.P. Intranasal administration of Mycoplasma hyopneumoniae antigen
WO1991018627A1 (en) 1990-05-29 1991-12-12 Smithkline Beecham Corporation Swine pneumonia vaccine and method for the preparation thereof
US6113916A (en) * 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
US5695769A (en) * 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
DK0669971T3 (da) 1991-11-15 2003-04-22 Pfizer Fremgangsmåde til fremstilling af Gram-negative bakterielle vacciner
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5534256A (en) * 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
JP3265095B2 (ja) * 1993-11-19 2002-03-11 本田技研工業株式会社 キャニスタ
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
DE19601754A1 (de) * 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) * 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
WO1998028333A2 (en) * 1996-12-20 1998-07-02 The Board Of Regents, The University Of Texas System USPA1 AND USPA2 ANTIGENS OF $i(MORAXELLA CATARRHALIS)
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
US6342231B1 (en) * 1998-07-01 2002-01-29 Akzo Nobel N.V. Haemophilus parasuis vaccine and diagnostic
US6632439B2 (en) * 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
PT2842569T (pt) * 2001-07-02 2019-06-17 Zoetis Services Llc Vacinação de dose única com mycoplasma hyopneumoniae
WO2003074026A1 (en) * 2002-03-07 2003-09-12 Biocompatibles Uk Limited Drug carriers comprising amphiphilic block copolymers
ITMI20030269A1 (it) * 2003-02-14 2004-08-15 Advance Holdings Ltd Sale di cetilpiridino di un agente antiinfiammatorio
US8052762B1 (en) * 2010-09-02 2011-11-08 Kelly Van Gogh, LLC Compositions for dyeing keratin-containing fibers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0315153A2 (en) * 1987-11-03 1989-05-10 Syntex (U.S.A.) Inc. Vaccine adjuvant
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
WO1995030437A1 (en) * 1994-05-10 1995-11-16 American Home Products Corporation Improved modified live brsv vaccine

Also Published As

Publication number Publication date
MY129765A (en) 2007-04-30
YU49303A (sh) 2006-08-17
CN1296095C (zh) 2007-01-24
KR100874119B1 (ko) 2008-12-15
NZ526904A (en) 2005-07-29
ES2283452T3 (es) 2007-11-01
US20120213816A1 (en) 2012-08-23
CZ307075B6 (cs) 2018-01-03
EP1343525B1 (en) 2007-04-18
JP2009073855A (ja) 2009-04-09
AR033410A1 (es) 2003-12-17
TWI308872B (en) 2009-04-21
JP5074656B2 (ja) 2012-11-14
HUP0400687A3 (en) 2004-10-28
RS51536B (sr) 2011-06-30
PL211174B1 (pl) 2012-04-30
EP1343525A2 (en) 2003-09-17
BG66213B1 (bg) 2012-05-31
WO2002049666A2 (en) 2002-06-27
ME00570A (en) 2011-12-20
KR20030065556A (ko) 2003-08-06
US20100119471A1 (en) 2010-05-13
US9238065B2 (en) 2016-01-19
DE60127994T2 (de) 2008-01-17
AU2899302A (en) 2002-07-01
BG107898A (bg) 2004-08-31
AU2002228993B2 (en) 2006-06-29
HU227431B1 (en) 2011-06-28
JP2004518655A (ja) 2004-06-24
ATE359813T1 (de) 2007-05-15
PT1343525E (pt) 2007-07-12
CY1106669T1 (el) 2012-05-23
MXPA03005357A (es) 2003-10-06
CN1489472A (zh) 2004-04-14
US20020131980A1 (en) 2002-09-19
DK1343525T3 (da) 2007-06-04
BR0116249A (pt) 2004-03-02
HRP20030585A2 (en) 2005-06-30
HK1056513A1 (en) 2004-02-20
US7666439B2 (en) 2010-02-23
US8187588B2 (en) 2012-05-29
BRPI0116249B1 (pt) 2016-06-14
WO2002049666A3 (en) 2003-02-06
ZA200305545B (en) 2004-10-18
US20070020296A1 (en) 2007-01-25
DE60127994D1 (de) 2007-05-31
HUP0400687A2 (hu) 2004-06-28
CZ20031721A3 (cs) 2004-04-14
ME00570B (me) 2011-12-20
PL363220A1 (en) 2004-11-15

Similar Documents

Publication Publication Date Title
HRP20030585B1 (en) Improved mycoplasma hyopneumoniae bacterin vaccine
RS54390B1 (sr) Kombinovana vakcina protiv mycoplasma hyopneumoniae i svinjskog cirkovirusa
IS7076A (is) Bólusetning með einföldum skammti af Mycoplasma hyopneumoniae, og notkun efnisins í lækningaskyni
EA200000584A3 (ru) Твердые фармацевтические композиции с контролируемым высвобождением, получаемые тепловым формованием
IL153655A0 (en) Polymeric micelle compositions
MY129263A (en) Vaccine composition
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
MXPA05009367A (es) Antagonistas del receptor opioide.
DK1147117T3 (da) Immunologiske adjuvansforbindelser
DK1606242T3 (da) Azidfri fremgangsmåde til fremstilling af 1,2-diaminoforbindelser
TW200505823A (en) CaSR antagonist
SE0201659D0 (sv) Modified release pharmaceutical formulation
ES2244617T3 (es) Vacunas a base de salmonelas en las cuales los genes ssa han sido inactivados.
SE0004053D0 (sv) N-type calcium channel antagonists for the treatment of pain
ATE308522T1 (de) Opioidrezeptorantagonisten
WO2002010343A3 (en) Temperature-sensitive live vaccine for mycoplasma hyopneumoniae
ES2182114T3 (es) Derivados azabiciclicos de la carbamoiloxi-multilina para empleo antibacteriano.
EP1583506A3 (en) Eye-drop vaccine containing copolymer 1 for therapeutic immunization
DE50210465D1 (de) Stabilisierte thermoplastische formmassen
ATE194753T1 (de) Hyperkinetische bewegungsstörung modulierender opiatrezeptor-antagonist
DE60005517D1 (de) Kaliumkanal-blockierende mittel
BR0210539A (pt) Processos de seleção e uso de vacinas de vetor antiartrópode
SG147465A1 (en) Vaccine
ATE329615T1 (de) Borrelia burgdorferi bacterin
IL153784A0 (en) Novel n-(2-phenyl-3-aminopropyl) naphthamides

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: ZOETIS W LLC, US

Owner name: WYETH LLC, US

PPPP Transfer of rights

Owner name: PAH W LLC, US

PNAN Change of the applicant name, address/residence

Owner name: ZOETIS W LLC, US

PNAN Change of the applicant name, address/residence

Owner name: ZOETIS SERVICES LLC, US

PNAN Change of the applicant name, address/residence

Owner name: ZOETIS SERVICES LLC, US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20181204

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20191203

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20201203

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20211211